Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bumetanide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | SLC12A2 | P55011 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | AQP1 | P29972 | 1/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 16/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bumetanide SCHEMBL27525 | 1.00 | KDM4E (1.00) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL4425232 | 1.00 | KDM4E (1.00) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL6239781 | 0.99 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL251062 | 0.99 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL2255359 | 0.99 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL23455698 | 0.99 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL28661289 | 0.99 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL28549675 | 0.98 | KDM4E (0.96) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL250621 | 0.98 | KDM4E (0.96) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| SCHEMBL11840406 | 0.97 | KDM4E (0.94) | KDM4EUSP2ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4426368-B1 | APPARATUS FOR EXTRACORPOREAL BLOOD TREATMENT | GAMBRO LUNDIA AB (SE) | 2025-11-26 | — | — | EP | claimed |
| EP-3877402-B1 | COMBINATION TREATMENT FOR HYPERTENSION | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-07-16 | — | — | EP | claimed |
| EP-3419612-B1 | HETEROCYCLIC SMALL MOLECULE INHIBITORS OF PENDRIN ION EXCHANGE AND PHARMACEUTICAL COMPOSITIONS | UNIV CALIFORNIA (US) | 2024-11-06 | — | — | EP | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| EP-3004873-B1 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | ASTUTE MEDICAL INC (US) | 2024-01-24 | — | — | EP | claimed |
| EP-3693054-B1 | REDUCING MOTILITY OF CANCER CELLS USING TUMOR TREATING FIELDS (TTFIELDS) | NOVOCURE GMBH (CH) | 2023-06-28 | — | — | EP | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| EP-3599243-B1 | 17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE | CVIE THERAPEUTICS LTD (TW) | 2023-04-12 | — | — | EP | claimed |
| EP-3544599-B1 | BROMIDE SOURCE FOR USE IN TREATING AUTISM SPECTRAL DISORDER | INST NAT SANTE RECH MED (FR) | 2022-08-17 | — | — | EP | claimed |
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | claimed |
| US-20250367150-A1 | PHARMACEUTICAL COMPOSITION | NEUROPRO THERAPEUTICS, INC. | 2025-12-04 | — | — | US | disclosed |
| EP-4648761-A1 | METHODS OF TREATMENT USING LOOP DIURETICS | scPharmaceuticals Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250339410-A1 | TREATMENT FOR AUTISM SPECTRUM DISORDER | STALICLA SA (CH) | 2025-11-06 | — | — | US | disclosed |
| WO-2025215115-A1 | COMPOUNDS FOR USE THE TREATMENT OF CANCER, NEURODEGENERATIVE DISEASES, PSYCHIATRIC DISORDERS, INFLAMMATION, EPILEPSY AND SEIZURES | B&A ONCOMEDICAL (FR) | 2025-10-16 | — | — | WO | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | disclosed |
| US-20220054526-A1 | Antisense Compounds Targeting Genes Associated with Cystic Fibrosis | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE | 2022-02-24 | — | — | US | disclosed |
| WO-2022036063-A2 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | THE BROAD INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | KDM4E 4313/4885USP2 2191/4885ALDH1A1 3084/4885 |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | KDM4E 4515/4885USP2 2107/4885ALDH1A1 4001/4885 |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | KDM4E 2426/4885USP2 3587/4885ALDH1A1 835/4885 |
| US-20250339410-A1 | TREATMENT FOR AUTISM SPECTRUM DISORDER | GABRQ, GABRB1, GABRB3 | KDM4E 892/4885USP2 1266/4885ALDH1A1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.